Please provide your email address to receive an email when new articles are posted on . The distance horizontal fusional facility test identified patients with acquired brain injuries. Future testing ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (VCYT) (Nasdaq: VCYT), a leading cancer diagnostics company, today announced it has met its targeted enrollment for the NIGHTINGALE trial, ...
Welcome to GOLF.com’s ClubTest Proving Ground, where Managing Equipment Editor Jonathan Wall and Senior Equipment Editor Ryan Barath put the latest designs and groundbreaking technology in the ...
Study also shows DecisionDx-SCC is being appropriately utilized by clinicians treating patients with cutaneous squamous cell carcinoma and one or more risk factors, as evidenced by first-year clinical ...
Veracyte Completes NIGHTINGALE Clinical Utility Trial Enrollment for Percepta Nasal Swab Lung Cancer Test Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced it has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results